Zealand Pharma is a biotech company that specializes in developing peptide-based medicines for metabolic and gastrointestinal diseases. With over 10 drug candidates in clinical development, Zealand’s pipeline is robust, including three candidates in late-stage development and one under regulatory review in the United States. The company’s flagship product is V-Go, an all-in-one insulin delivery option for diabetes patients. Zealand has also entered into collaboration agreements with Boehringer Ingelheim and Alexion Pharmaceuticals, expanding the reach of their peptide therapeutics.